Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer

Targeted therapies have often given disappointing results when used as single agents in solid tumors, suggesting the importance of devising rational combinations of targeted drugs. We hypothesized that construction of such combinations could be guided by identification of growth and survival pathways whose activity or expression become upregulated in response to single-agent drug treatment. We mapped alterations in signaling pathways assessed by gene array and protein phosphorylation to identify compensatory signal transduction pathways in prostate cancer xenografts treated with a MAP/ERK kinase (MEK) inhibitor PD325901. In addition to numerous components of the extracellular signal–regulated kinase (ERK) signaling pathway, components of the IKK, hedgehog, and phosphoinositide 3-kinase/Akt/mTOR pathways were upregulated following treatment with PD325901. Combinations of PD325901 with inhibitors of any one of these upregulated pathways provided synergistically greater growth inhibition of in vitro cell growth and survival than the individual drugs alone. Thus, the identification of compensatory signal transduction pathways paves the way for rational combinatorial therapies for the effective treatment of prostate cancer. Mol Cancer Ther; 10(9); 1581–90. ©2011 AACR.

[1]  M. Villaronga,et al.  Notch signaling: a potential therapeutic target in prostate cancer. , 2008, Current cancer drug targets.

[2]  N. Saijo.  What are the reasons for negative phase III trials of molecular‐target‐based drugs? , 2004, Cancer science.

[3]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[4]  Pierre Baldi,et al.  Computational Prediction and Experimental Verification of New MAP Kinase Docking Sites and Substrates Including Gli Transcription Factors , 2010, PLoS Comput. Biol..

[5]  Dung-Fang Lee,et al.  Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy , 2008, Clinical Cancer Research.

[6]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[7]  Maria Kasper,et al.  Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. , 2009, Cancer research.

[8]  H. Kitano.  Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.

[9]  Raymond P Perez,et al.  New targets and challenges in the molecular therapeutics of cancer. , 2006, British journal of clinical pharmacology.

[10]  F. S. French,et al.  Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.

[11]  W. Hahn,et al.  CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. , 2010, Molecular endocrinology.

[12]  Madhusudan Natarajan,et al.  A global analysis of cross-talk in a mammalian cellular signalling network , 2006, Nature Cell Biology.

[13]  D. Euhus,et al.  Tumor measurement in the nude mouse , 1986, Journal of surgical oncology.

[14]  C. Dierks.  GDC-0449--targeting the hedgehog signaling pathway. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[15]  W. Bushman,et al.  Hedgehog signaling in prostate growth and benign prostate hyperplasia , 2007, Current urology reports.

[16]  S. Thomson,et al.  Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. , 2008, Cancer research.

[17]  T. Hughes,et al.  Signals and systems , 2006, Genome Biology.

[18]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[19]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[20]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[21]  E. Petricoin,et al.  Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. , 2003, Advances in experimental medicine and biology.

[22]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[23]  J. Engelman,et al.  Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors , 2009 .

[24]  Gerald C. Chu,et al.  GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. , 2009, Genes & development.

[25]  B. Williams,et al.  Wnt signaling and prostate cancer. , 2008, Current drug targets.

[26]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[27]  M. Wilkerson,et al.  Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.

[28]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[29]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[30]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[31]  R. Roth,et al.  Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation and Function by Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[32]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[33]  Nicoletta Kessaris,et al.  Cooperation between sonic hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical precursors , 2004, Development.

[34]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[35]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[36]  M. Rubin,et al.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. , 2009, Journal of proteome research.

[37]  T. Slaga,et al.  The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. , 2002, Journal of cell science.

[38]  Jingwu Xie,et al.  Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells* , 2007, Journal of Biological Chemistry.

[39]  M. Umeda,et al.  Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. , 1989, Toxicology in vitro : an international journal published in association with BIBRA.

[40]  E. Bissonette,et al.  Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. , 2003, Cancer research.

[41]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[42]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[43]  Gabriel S. Eichler,et al.  Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. , 2007, Cancer research.

[44]  A. Maitra,et al.  Urological Survey UROLOGICAL ONCOLOGY: PROSTATE CANCER Hedgehog Signalling in Prostate Regeneration, Neoplasia and Metastasis , 2005 .